Search for dissertations about: "Progressive Multiple Sclerosis"
Showing result 11 - 15 of 61 swedish dissertations containing the words Progressive Multiple Sclerosis.
-
11. Acquired epilepsy in Multiple sclerosis: a nationwide register-based investigation into prognosis and treatment
Abstract : The prevalence of epilepsy in persons with multiple sclerosis (MS) is thrice that of the general population. The association between epilepsy and MS prognosis and its management are however largely unknown. The prevalence of concomitant MS and epilepsy is low, making recruitment of sufficient numbers of patients for single-centre studies difficult. READ MORE
-
12. Brain parenchymal fraction in healthy individuals and in clinical follow-up of multiple sclerosis
Abstract : Background Multiple sclerosis (MS) is an autoimmune disease characterised by inflammatory damage to the central nervous system (CNS). Accumulated CNS injury can be quantified as brain atrophy, definable as a reduction in brain parenchymal fraction (BPF). BPF correlate with disability in MS and is used routinely as an endpoint in clinical trials. READ MORE
-
13. MRI quantification of multiple sclerosis pathology
Abstract : Background: Multiple sclerosis (MS) is a chronic neuroinflammatory and neurodegenerative disease and a common cause of neurologic disability. MS pathology is characterized by demyelination, neuroaxonal loss and atrophy. READ MORE
-
14. Susceptibility gene mapping in multiple sclerosis
Abstract : Multiple sclerosis (MS) is a chronic inflammatory disease characterized by relapsing or progressive demyelination of the central nervous system (CNS). Increasing evidence supports that genetic factors confer susceptibility to MS resulting in an unknown mode of inheritance as a complex trait. READ MORE
-
15. Studies of the Biology of Intrathecal Treatment in Progressive MS
Abstract : Background: Multiple Sclerosis (MS) is a chronic, inflammatory, autoimmune disease, affecting the central nervous system (CNS). About 85% of afflicted present with a relapsing-remitting form of the disease (RRMS), for which a breakthrough in treatment was made in 2008 with rituximab, an antibody directed towards CD20, a surface antigen on B-cells. READ MORE